This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06148/identifier/pubchem-compound/
n18http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/drug/DB06148/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/drug/DB06148/identifier/iuphar/
n8http://linked.opendata.cz/resource/drugbank/drug/DB06148/identifier/drugbank/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06148/identifier/guide-to-pharmacology/
n21http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n7http://linked.opendata.cz/resource/drugbank/drug/DB06148/identifier/chemspider/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/drug/DB06148/identifier/chebi/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n6http://linked.opendata.cz/resource/drugbank/drug/DB06148/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB06148/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06148
rdf:type
n3:Drug
n3:description
A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favor of Mirtazapine.
n3:generalReferences
# Koyama E, Chiba K, Tani M, Ishizaki T: Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8764331 # de Boer TH, Nefkens F, van Helvoirt A, van Delft AM: Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996 May;277(2):852-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8627567 # Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V: A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol. 1997 Apr;49(4):403-11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9232538
n3:group
approved
n3:halfLife
10-17 hours
n3:indication
For the treatment of depression.
owl:sameAs
n13:DB06148 n21:DB06148
dcterms:title
Mianserin
adms:identifier
n6:Mianserin n7:4040 n8:DB06148 n9:51137 n10:PA134687937 n11:4184 n14:135 n15:135 n16:46508096
n3:mechanismOfAction
Mianserin's mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
n3:synonym
Mianserina Mianserinum Mianseryna Mianserine 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,F)pyrazino(1,2-a)azepine
n3:toxicity
Oral rat LD<sub>50</sub>: 780mg/kg
n3:proteinBinding
90%
n3:salt
n17:hasConcept
n18:M0013724
n3:IUPAC-Name
n4:271B4904-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B490A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4909-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4906-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4907-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4908-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4902-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4900-363D-11E5-9242-09173F13E4C5 n4:271B4903-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4901-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:N06AX03
n3:H-Bond-Acceptor-Count
n4:271B4910-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4911-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B490B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B490C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B490E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B490D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B490F-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
24219-97-4
n3:category
n3:Bioavailability
n4:271B4915-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4917-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4918-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4914-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4913-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4916-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4905-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4912-363D-11E5-9242-09173F13E4C5